COMMUNIQUÉS West-GlobeNewswire

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
25/06/2026
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
DeepView® System Highlighted at the 2026 British Burn Association Annual Conference
25/06/2026
Dr. Jeffrey Carter Awarded BBA Oral Presentation 1st Prize for his Paper on the Use of Multi-Spectral Imaging with Artificial Intelligence for Burn Wounds DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
25/06/2026
Psychedelic Science 2027 (PS27) convenes May 3–7, 2027, at the Colorado Convention Center in Denver under the theme “Bridging Promise & Practice” PS27’s speaker submission is now open through Friday, September 18, [...]
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
25/06/2026
Innovative Start-Up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc [...]
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
25/06/2026
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the [...]
TRUE-See Selected to Participate in Microsoft for Start-Ups Azure AI Program to Accelerate Innovation and Growth
25/06/2026
Includes $350,000 in non-dilutive Microsoft Azure AI credits for TRUE-See’s R&D that is incorporating AI to increase the utility and diagnostic accuracy of medical photography TRUE-See’s unique patented technology [...]
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes
25/06/2026
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within [...]
Glass House Brands Announces Uplist to NYSE
25/06/2026
LONG BEACH, Calif. and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the “Company”) (CBOE CA: GLAS.A.U) (OTCQX: GLASF) today announced that its subordinate voting shares (the “ [...]
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25/06/2026
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase [...]
Survey Exposes a Crisis of Avoidance in Family Caregiving
25/06/2026
Older Adults Want to Age at Home: Just 1 in 5 Have Told Loved Ones What They Actually Want LOUISVILLE, Ky., June 25, 2026 (GLOBE NEWSWIRE) -- A comprehensive new national survey commissioned by LogicMark, Inc. (OTC: [...]
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
25/06/2026
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, [...]
New PerfectServe Research: 85% of Healthcare Leaders Want to Switch Their Contact Center Vendors, But Most Feel Trapped
25/06/2026
Survey of 105 IT and operational leaders reveals tech fragmentation that harms patient experience and complicates operators’ working environment MIAMI, June 25, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a leading [...]
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
25/06/2026
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage [...]
NIMA and RA Capital Launch First-of-Its-Kind Workplace Pilot to Support Employees with Celiac Disease
25/06/2026
New benefit program provides NIMA’s portable gluten sensors at no cost to help employees and their families navigate gluten-free living with greater confidence. BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- NIMA Partners, [...]
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
25/06/2026
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by [...]
Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program
25/06/2026
Independent DMC recommends continued conduct of the MUSIC-HFpEF study without protocol modification following scheduled review of accumulated clinical data; randomized HFrEF Phase 2 study also reviewed with no safety [...]
The LaVie Institute Introduces Less-Invasive Breast Augmentation Technique with Rapid Recovery
25/06/2026
New muscle-preserving technique is designed to help eligible patients resume work, family responsibilities, and daily activities in days rather than weeks DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- The LaVie Institute [...]
La Croix-Rouge canadienne et Walmart Canada donnent le coup d’envoi à la campagne de financement annuelle
25/06/2026
Les fonds recueillis permettront d’aider les communautés partout au Canada lors de situations d’urgence OTTAWA, 25 juin 2026 (GLOBE NEWSWIRE) -- Alors que le Canada connaît un début de saison des feux de forêt occupé et [...]
Eliaz Therapeutics Highlights Selective Galectin-3 Removal in Sepsis, Advances XGAL-3® Program
25/06/2026
Santa Rosa, United States, June 25, 2026 (GLOBE NEWSWIRE) -- Eliaz Therapeutics Announces Publication Highlighting Selective Galectin-3 Removal Approach in Sepsis and Advancement of XGAL-3 Development Program Company [...]

Pages